Clinical trials: PCD, open to volunteers
Nasopharyngeal Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation.
- Trial name
- NCT05628922
- Testing
- Toripalimab, Induction chemotherapy and concurrent chemoradiation
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Chronic Obstructive Pulmonary Disease, Asthma
A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine
Chronic inflammatory pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and interstitial lung diseases (ILD) are…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Bronchiectasis, Cystic Fibrosis
- Trial name
- PALMIRE (NCT07274631)
- Testing
- Non applicable
- Where
- France
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Cervical Cancer
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT07216703
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab
- Where
- 191 sites in United States, Argentina and 27 more
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC
Spontaneous Intracranial Hypotension
CVFs in SIH: EID vs. PCD CTM
The purpose of this research study is to compare two types of Computed Tomography Myelography (CTM) scans, one on the photon counting detector scanner (called PCD-CTM) and the other on the energy integrating detector scanner…
- Trial name
- NCT07582744
- Testing
- photon counting detector CT myelography (PCD- CTM), energy integrating detector CT myelography (EID-CTM)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Duke University
XIAP Deficiency
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency.
- Trial name
- NCT07433621
- Testing
- Quercetin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Idiopathic Bronchiectasis
Primary Ciliary Dyskinesia in Adult Bronchiectasis
The purpose of this study is to help determine how often primary ciliary dyskinesia (PCD) is present but undiagnosed in adults with bronchiectasis.
- Trial name
- NCT07566611
- Testing
- Nasal Nitric Oxide Measurement, Nasopharyngeal (Nasal) Samples
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Indiana University
Cancer of Cervix, Apoptosis
Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.
- Trial name
- EPIcol (NCT06147960)
- Testing
- Immunohistochemistry
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers.
- Trial name
- NCT06228066
- Testing
- Lurbinectedin, Avelumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Aortic Valve Stenosis and Insufficiency, Coronary Artery Disease(CAD)
Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial
The goal of this clinical trial is to determine whether a non-invasive coronary assessment strategy using photon-counting detector computed tomography (PCD-CT) is non-inferior to invasive coronary angiography (ICA) for evaluating…
- Conditions
- Aortic Valve Stenosis and Insufficiency, Coronary Artery Disease(CAD), Transcatheter Aortic Valve Replacement (TAVR)
- Trial name
- TAVR-CT (NCT07107568)
- Testing
- Standard Invasive Coronary Angiography, PCD-CT-Guided Diagnostic Strategy
- Where
- 2 sites in Austria
- Volunteers
- 700 people
- Sponsor
- Medical University Innsbruck
Primary Ciliary Dyskinesia, Healthy
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
The purpose of this study is to look at children with PCD and see if they have another condition called "bronchial hyperresponsiveness".
- Trial name
- BHR (NCT07288827)
- Testing
- Lung Function Testing, Phlebotomy, Allergy skin prick testing
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Indiana University
Esophageal Squamous Cell Carcinoma
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants…
- Trial name
- NCT05319730
- Testing
- Paclitaxel, Irinotecan, Pembrolizumab
- Where
- 58 sites in United States, Brazil and 12 more
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Ciliary Dyskinesia (PCD)
Malnutrition and Sarcopenia Among Primary Ciliary Dyskinesia
The prevalence and causes of malnutrition and sarcopenia in children and adolescents with Primary ciliary dyskinesia (PCD) have not been sufficiently elucidated.
- Trial name
- Malnutrition (NCT07740538)
- Testing
- Physical assessments of individuals
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Izmir Democracy University
Multiple Sclerosis
TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis
A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS.
- Trial name
- TWEAK (NCT03974997)
- Testing
- Determination of the circulating serum concentration of cytoquine TWEAK
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.
- Trial name
- TroFuse-033 (NCT06952504)
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 268 sites in United States, Argentina and 32 more
- Volunteers
- 1,123 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Ciliary Dyskinesia (PCD)
A Qualitative Study Investigating the Lived Experiences and Impact of Reproductive Issues in Adults With Primary Ciliary Dyskinesia
Study involving undertaking research interviews with adults who have primary ciliary dyskinesia in the UK about their views and experiences of fertility, pregnancy and parenthood
- Trial name
- NCT07357558
- Testing
- Interview only
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Prostate Cancer
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day.
- Trial name
- NCT03753243
- Testing
- Pembrolizumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mark Garzotto, MD
Carcinoma, Non-Small Cell Lung
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
- Trial name
- ARTEMIDELung04 (NCT06868277)
- Testing
- Rilvegostomig, Pembrolizumab
- Where
- 304 sites in United States, Argentina and 25 more
- Volunteers
- 830 people
- Sponsor
- AstraZeneca
Kartagener Syndrome
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mutations that adversely affect…
- Trial name
- NCT00807482
- Where
- United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Lung Cancer, Non-small Cell Lung Cancer
Effects of Infusion Timing on Treatment Response in Solid Tumors
This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer
- Trial name
- TIMED (NCT07630168)
- Testing
- PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Coronary Artery Disease
Evaluation of PCD-CT Based Image Parameters in the Assessment and Quantification of Coronary Artery Disease
The goal of this observational study is to learn about a new type of computed tomography (Photon-Counting Detector CT) in patients with coronary artery disease.
- Trial name
- EPIPHANY (NCT05877768)
- Testing
- Photon Counting Detector Coronary Computed Tomography Angiography
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- University Medical Center Mainz